Navigation Links
Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
Date:3/19/2013

ecutive Officer of Savient.  "Part of this long-term corporate strategy is to ensure that the true value of this highly effective orphan drug is reflected appropriately.  The recent 30% price increase of KRYSTEXXA represents management's commitment to execute upon this strategy and continue to build long-term value for our stakeholders."

Fourth Quarter Operational Highlights and Recent Developments:

  • Announced additional new data demonstrating KRYSTEXXA-treated refractory chronic gout patients experienced significantly improved health-related quality of life
  • Announced new data from an open-label extension (OLE) study published in the Annals of the Rheumatic Diseases reinforcing the safety and efficacy profile of KRYSTEXXA
  • Announced the elections of Robert G. Savage and Dr. David Meeker to the Company's board of directors
  • Completed study of KRYSTEXXA in dialysis patients, and anticipate data to be presented at a major scientific meeting later this year
  • Received European Commission marketing authorization in January 2013 for KRYSTEXXA® for the treatment of certain patients with chronic tophaceous gout in the EU
  • Announced a co-promotion agreement with Swedish Orphan Biovitrum AB (Sobi) for Kineret® (anakinra) in the U.S.
  • Financial Results of Operations for the Three Months Ended December 31, 2012Net revenues increased $1.2 million, or 33%, to $4.9 million for the three-month period ended December 31, 2012, from $3.7 million for the three-month period ended December 31, 2011, as a result of increasing awareness and acceptance of KRYSTEXXA among our target customer base, and to a lesser extent, the impact of our price increases.  Over the past year, we have increased the selling price of KRYSTEXXA by approximately 29% from the original list price of $2,300 per vial to $2,962 per vial.  We further increased the selling price in 2013 by
    '/>"/>

    SOURCE Savient Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results
    2. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
    3. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
    4. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
    5. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
    6. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
    7. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
    8. AVANIR Pharmaceuticals To participate in two conferences in March
    9. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
    10. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
    11. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... 22, 2014 Grace Century, a private ... projects, announces the addition of Dr. Yousef “Josh” ... advisory team. Dr. Siddiqui will provide further healthcare expertise ... graduate of University College Medical School in ... medicine in 2001. With further certification as a General ...
    (Date:10/22/2014)... According to new market research report ... Integration, Deployment & Support), by Service Model (SaaS, ... Others (Hybrid & Community)) - Global Forecast to ... Cloud Professional Services Market into various sub-segments with ... also identifies the drivers and restraints for this ...
    (Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
    (Date:10/22/2014)... Research and Markets  has announced the addition of ... Geography - Global Analysis and Forecast (2014 - 2020)" ... electronics, also called as polymer electronics or plastic electronics, ... small conductive molecules and electrically conductive polymers. It is ... carbon based, made using synthetic strategies developed in the ...
    Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
    ... a currently available yet underused vaccine against typhoid fever is ... vaccinees. The study, conducted by the International Vaccine ... and Enteric Diseases (NICED) in Kolkata, India, was published in ... of Medicine (NEJM). The IVI, based in Seoul, Korea, ...
    ... , , RICHMOND, Calif., July 22 ... that the company will release its second quarter 2009 financial results ... release will be followed by a conference call at 5:00 p.m. ... webcast. During the conference call, the company will review the financial ...
    ... , , , , ... a development-stage company focused on novel biopolymer implant therapies to treat ... the corporation to CardioPolymers, Inc. , , ... "The name change, which is effective immediately, better reflects our focus ...
    Cached Biology Technology:Vi typhoid vaccine proves highly effective in young children 2Vi typhoid vaccine proves highly effective in young children 3Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast 2Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast 3Symphony Medical Changes Name to CardioPolymers, Inc. 2
    (Date:10/16/2014)... are anything but sustainable: environmental damage to soil ... increasingly evident. Despite their disadvantages, however, monocultures remain ... the sole possibility of achieving higher yields in ... an ecology professor at the University of Zurich, ... forestry. After all, a new study carried out ...
    (Date:10/15/2014)... N.Y. , Oct. 15, 2014 ... solutions for home and community-based care, today announced ... of implementing Sandata,s Santrax® Electronic Visit Verification™ Solution ... Services is a home health company founded in ... Texas . The study ...
    (Date:10/15/2014)... The Ebola virus is spreading rapidly and to an ... experienced in the past and the virus shows a ... been recorded before. For this reason, the German National ... of Science and Engineering, and the Union of the ... statement on the Ebola epidemic today. , In the ...
    Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Sandata Announces Case Study with Quality Care Services, Inc. 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
    ... researchers have found that years after experiencing childhood ... than expected in their elderly counterparts, but rather ... commensurate with normal aging. , "Other researchers have ... later in life, but we've actually found it ...
    ... of a nation-wide study published in the latest issue ... Physicians in AIDS Care (JIAPAC), HIV positive patients and ... and how it's treated. , The study uncovered differences ... of treatment, the various goals of treatment, and even ...
    ... of poultry flocks could make the spread of deadly ... at the Universities of Edinburgh and Warwick have found. ... are effective on individual birds, the disease is likely ... been protected. The study, published in Nature journal, is ...
    Cached Biology News:Survivors of childhood polio do well decades later as they age 2Bird flu study highlights need to vaccinate flocks effectively 2
    ...
    ... This modular benchtop fume hood ... allowing safe indoor release of ... most organic contaminants. Configurations are ... flow; options include final HEPA ...
    ...
    ... The Staccato Series of systems provide ... drug discovery , genomics, proteomics and drug ... three base configurations; Mini Workstation Series, Application ... Sciclone ELISA Station is a remarkably compact ...
    Biology Products: